List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11831373/publications.pdf

Version: 2024-02-01

713013 623188 21 494 14 21 citations h-index g-index papers 555 21 21 21 docs citations citing authors all docs times ranked

#	Article	IF	Citations
1	Translation of animal endocannabinoid models of PTSD mechanisms to humans: Where to next?. Neuroscience and Biobehavioral Reviews, 2022, 132, 76-91.	2.9	18
2	Dopamine, endocannabinoids and their interaction in fear extinction and negative affect in PTSD. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 105, 110118.	2.5	36
3	Endocannabinoid reactivity to acute stress: Investigation of the relationship between salivary and plasma levels. Biological Psychology, 2021, 159, 108022.	1.1	15
4	Cannabinoid polymorphisms interact with plasma endocannabinoid levels to predict fear extinction learning. Depression and Anxiety, 2021, 38, 1087-1099.	2.0	21
5	Chloroform-based liquid-liquid extraction and LC–MS/MS quantification of endocannabinoids, cortisol and progesterone in human hair. Journal of Pharmaceutical and Biomedical Analysis, 2021, 201, 114103.	1.4	15
6	The effects of acute stress on attentional networks and working memory in females. Physiology and Behavior, 2021, 242, 113602.	1.0	1
7	BDNF genotype Val66Met interacts with acute plasma BDNF levels to predict fear extinction and recall. Behaviour Research and Therapy, 2021, 145, 103942.	1.6	4
8	Brain-derived neurotropic factor and cortisol levels negatively predict working memory performance in healthy males. Neurobiology of Learning and Memory, 2020, 175, 107308.	1.0	4
9	Simultaneous quantification of endocannabinoids, oleoylethanolamide and steroid hormones in human plasma and saliva. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2020, 1152, 122252.	1.2	28
10	Cannabinoid interventions for PTSD: Where to next?. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 93, 124-140.	2.5	52
11	Commentary on "Sex differences in the effect of cannabinoid type 1 receptor deletion on locus coeruleusâ€norepinephrine neurons and corticotropin releasing factorâ€mediated responsesâ€. European Journal of Neuroscience, 2019, 49, 1210-1211.	1.2	3
12	ERP correlates of attentional processing in spider fear: evidence of threat-specific hypervigilance. Cognition and Emotion, 2018, 32, 437-449.	1.2	5
13	Modulation of the endocannabinoid system by sex hormones: Implications for posttraumatic stress disorder. Neuroscience and Biobehavioral Reviews, 2018, 94, 302-320.	2.9	45
14	Motivations for new psychoactive substance use among regular psychostimulant users in Australia. International Journal of Drug Policy, 2017, 43, 23-32.	1.6	36
15	Trends in reports of driving following illicit drug consumption among regular drug users in Australia, 2007–2013: Has random roadside drug testing had a deterrent effect?. Accident Analysis and Prevention, 2017, 104, 146-155.	3.0	17
16	I like the old stuff better than the new stuff? Subjective experiences of new psychoactive substances. International Journal of Drug Policy, 2017, 40, 44-49.	1.6	22
17	New psychoactive substance use among regular psychostimulant users in Australia, 2010–2015. Drug and Alcohol Dependence, 2016, 161, 110-118.	1.6	46
18	Chronic cannabis use and ERP correlates of visual selective attention during the performance of a flanker go/nogo task. Biological Psychology, 2015, 110, 115-125.	1.1	15

#	Article	IF	CITATIONS
19	The rise of new psychoactive substance use in Australia. Drug Testing and Analysis, 2014, 6, 846-849.	1.6	70
20	Detouring Civil Liberties?. Griffith Law Review, 2010, 19, 330-349.	0.6	9
21	Factors associated with driving under the influence of alcohol and drugs among an Australian sample of regular ecstasy users. Drug and Alcohol Dependence, 2009, 100, 24-31.	1.6	32